RxDoctor Payments DataLook up a doctor →

Erin Sibben Stewart, NP

Family · Euclid, OHNPI 1871109595

Payments from drug & device makers

$15,902in general payments, 2019–2025

Across 837 payments — averaging $19.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$1K
  • AstraZeneca$1K
  • AbbVie$1K
  • GSK$1K
  • Novo Nordisk$966
  • Bayer$723
  • plus $9K from 50 others

What the payments were for

  • Food & beverage$15,79499%
  • Education$1081%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Lilly USA, LLC87$1,386
AstraZeneca(2 entities)63$1,350
AbbVie78$1,291
GSK67$1,182
Novo Nordisk63$966
Bayer26$723
Pfizer44$714
Otsuka America Pharmaceutical, Inc.26$558
Amgen(2 entities)22$551
Phathom Pharmaceuticals, Inc.19$513
Merck27$504
Novartis26$459
E.r. Squibb & Sons, L.L.C.27$452
Lundbeck LLC22$407
Exact Sciences15$363
Abbott15$345
Corcept Therapeutics12$340
Johnson & Johnson9$340
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)16$303
Boehringer Ingelheim17$282
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC15$274
Teva Pharmaceuticals USA, Inc.14$247
Sumitomo Pharma America, Inc.12$216
Alkermes, Inc.10$215
Astellas Pharma US Inc7$204
Dexcom, Inc.10$187
Sunovion Pharmaceuticals Inc.14$170
Nestle Healthcare Nutrition Inc.8$125
Takeda Pharmaceuticals U.S.A., Inc.7$123
Sanofi-aventis U.S. LLC7$122
Vivus LLC6$104
Optinose US, Inc.4$82
Aimmune Therapeutics, Inc.4$68
Vanda Pharmaceuticals Inc.2$61
Biohaven Pharmaceutical Holding Company Ltd.3$59
Biohaven Pharmaceuticals, Inc.3$57
Eisai Inc.3$53
Neurocrine Biosciences, Inc.3$49
Amarin Pharma, Inc.3$48
Avanir Pharmaceuticals, Inc.3$43
Mylan Specialty L.p.2$42
Abiomed1$41
Xeris Pharmaceuticals, Inc.2$38
UCB, Inc.1$25
Mannkind Corporation1$25
Zealand Pharma US, Inc.1$22
Scilex Pharmaceuticals Inc.1$22
Nabriva Therapeutics, PLC1$20
Medtronic1$19
Esperion Therapeutics, Inc.1$19
Paratek Pharmaceuticals, Inc.1$18
Axsome Therapeutics, Inc.1$18
Regeneron Healthcare Solutions, Inc.1$17
Radius Health, Inc.1$15
Ultragenyx Pharmaceutical Inc.1$14
Sun Pharmaceutical Industries Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$15,902 in reported general payments places this provider in the 95th percentile of 6,812 family providers in Ohio.

See all family providers in Ohio

Medicare billing

Part B allowed, 2024
$118,177
Medicare patients
411
Services billed
1,313

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin133$120,633
OzempicSemaglutide86$108,246
EliquisApixaban148$106,508
MounjaroTirzepatide77$96,088
Trelegy ElliptaFluticasone/Umeclidin/Vilanter103$94,231
TrulicityDulaglutide66$93,602
FarxigaDapagliflozin Propanediol38$45,473
JanuviaSitagliptin Phosphate31$27,862
TradjentaLinagliptin31$27,773
RybelsusSemaglutide20$26,317
GemtesaVibegron23$22,855
LinzessLinaclotide23$22,830
EntrestoSacubitril/Valsartan11$19,640
MyrbetriqMirabegron20$15,800
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr23$14,967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$1,386$189,689143 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat, Synjardy Xr$282$175,483193 claims
Novo NordiskOzempic, Rybelsus$966$134,563106 claims
PfizerEliquis, Premarin$714$110,517162 claims
GSKTrelegy Ellipta, Anoro Ellipta$1,182$109,198126 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$1,350$60,14967 claims
MerckJanuvia$504$27,86231 claims
Sumitomo Pharma America, Inc.Gemtesa$216$22,85523 claims
AbbVieLinzess$1,291$22,83023 claims
NovartisEntresto$459$19,64011 claims
Astellas Pharma US IncMyrbetriq$204$15,80020 claims
Johnson & JohnsonXarelto$340$9,58111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,812 family providers in Ohio.

Other family in Euclid

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →